Mar. 20 at 11:00 AM
$OKUR This is the safety profile of Relays pan-mutant inhibitor, which has BTD from FDA. With this profile they plan to go into 1L with a CDK4/6. THe framing here is insane. This is not a clean safety profile at all. Compared to Alpelisib this is certainly favourable, but its not a favourable safety profile, especially when u put CDK4/6 side effects on top of that, which they plan to do in 1L. I had to look up "Dysgeusia", it means that you have a constant metallic/bitter taste in your mouth. This is a clear symptom caused by wild-type inhibition, same with Hyperglycemia. IMO OKUR can potentially have 2/3 to 1/3 of these side effects, cause it has a much higher specificy for mutant than wild type compared to Relay. However, the DIarrhea issue will probably look the same or only a little bit better. Relays side effects are in most cases not severe, however they reduce QoL A LOT. That has become a very important aspect for Docs, Patients and FDA.
https://relaytx.com/wp-content/uploads/2026/03/Pres-90O_Varkaris-ESMO-TAT-2026_12mar2026_FINALr.pdf
